NVO240830C139000
- 0.25
- -0.19-43.18%
Novo-Nordisk A/S Newsroom
Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate
AI Gold Rush Is Just Beginning. Why Nvidia, AMD, and Co. Can Ride It.
Danish police: The fire at novo-nordisk (NVO.US) in Kalundborg is not related to crime.
Local police chief Per Severs said that the authorities were unable to determine the exact cause of the fire at the Novo Nordisk Kalundborg factory on May 16th.
Biden Commends Eli Lilly for Cheaper Zepbound Version, Vows to Negotiate Lower Obesity Drug Prices
After the launch of the "Zepbound" in small bottles by Eli Lilly and Co, the stock price of Hims & Hers (HIMS.US), which gained popularity with its generic version of weight loss drugs, plummeted.
On Tuesday, Eli Lilly and Co announced the launch of a cheaper version of its popular weight loss drug Zepbound, followed by a sharp drop in the stock price of Hims & Hers Health.
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
Is the weight loss drug "Kaijuan"? Eli Lilly is selling Zepbound small bottles at a 50% discount.
It may have a positive impact on the sales of Eli Lilly and Co.
Medicare Coverage of Novo Nordisk's Wegovy Could Cost up to $145B Annually
Looking At Novo Nordisk's Recent Unusual Options Activity
Weight Loss Drug Developers Slump as Eli Lilly Slashes Cost of Some Zepbound Doses
Walgreens, Hims Stocks Drop as Lilly Rolls Out Cheap Weight-loss Drugs
Eli Lilly Offers a Cheaper Form of Zepbound. Why Hims & Hers Stock Is Falling.
Eli Lilly Is Offering a Cheaper Form of Zepbound. What It Means for Hims & Hers Stock. -- Barrons.com
The price is only 50% of the normal dose! Eli Lilly (LLY.US) has launched a heavyweight weight loss miracle drug "small bottle version".
The monthly price for small bottles sold through LillyDirect is $399 or $549.
Obesity Drugs' Next Wave: These Companies Could Snag 20% of GLP-1 Market, Analysts Say
Novo Nordisk has submitted an application for the new indication of "Simeglutide" to be listed in China.
On August 26, the latest announcement on the CDE official website disclosed that novo-nordisk a/s's application for marketing approval of Semaglutide injection for a new indication has been accepted, with no specific indication information disclosed yet.
There are many followers in the weight loss drug market, but Novo Nordisk (NVO.US) and Eli Lilly (LLY.US) will maintain a "two-horse race" situation.
Although other pharmaceutical companies are also preparing to launch GLP-1 class weight-loss drugs, they are unlikely to have a significant impact on the current dominant market positions of novo-nordisk a/s and eli lilly and co.
Why Viking Therapeutics Is Thriving in the $150 Billion Weight Loss Drug Market
Eli Lilly, Novo Nordisk to Maintain 'Two Horse Race' in GLP-1 Weight Loss Market
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets